Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMAN trial of early CAR-T intensification versus standard first-line therapy in high-risk mantle cell lymphoma
2022-502405-15-01Phase 2Authorised
- Sponsor
- LMU Klinikum
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of brexucabtagene autoleucel, ibrutinib and rituximab in mantle cell lymphoma (MCL) (2 arms), sponsored by LMU Klinikum. Primary endpoint: Failure-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
brexucabtagene autoleucelibrutinibrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2022-502405-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502405-15-01.